In Europe and the USA, the mean frequency of celiac disease (CD) in the general population is approximately 1%, with some regional differences, the reasons for which remain elusive. A similar disease prevalence has been found in other countries mostly populated by individuals of European origin, e.g. Australia and Argentina. In Western countries, a true rise in overall CD prevalence of CD has been documented. CD is a common disorder in North Africa, the Middle East and India; however, the diagnostic rate is low in these countries due to low availability of diagnostic facilities and poor disease awareness. The highest CD prevalence in the world (5.6%) has been described in an African population originally living in Western Sahara, the Saharawi, of Arab-Berber origin. The reasons for this high CD frequency are unclear but could be primarily related to recent dietary changes and genetic factors, given the high level of consanguinity of this population. Further studies are needed to quantify the incidence of the celiac condition in apparently ‘celiac-free' areas such as Sub-Saharan Africa and the Far East. In many developing countries, the frequency of CD is likely to increase in the near future given the diffuse tendency to adopt Western, gluten-rich dietary patterns. As most cases currently escape diagnosis all over the world, an effort should be made to increase the awareness of CD polymorphism. A cost-effective case-finding policy and new strategies of mass CD screening could significantly reduce the morbidity and mortality associated with untreated disease. The current high prevalence of CD is just the last link in a chain of events started about 10,000 years ago after wheat domestication and diffusion from the Middle East. We hypothesize different mechanisms to explain the so-called evolutionary celiac paradox of co-localization of gluten consumption and HLA CD-predisposing genotypes.

1.
Fasano A, Catassi C: Clinical practice. Celiac disease. N Engl J Med 2012;367:2419-2426.
2.
Catassi C, Gatti S, Fasano A: The new epidemiology of celiac disease. J Pediatr Gastroenterol Nutr 2014;59(suppl 1):S7-S9.
3.
Mustalahti K, Catassi C, Reunanen A, et al: The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med 2010;42:587-595.
4.
Fasano A, Berti I, Gerarduzzi T, et al: Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Int Med 2003;163:286-292.
5.
Ivarsson A, Myléus A, Norström F, et al: Prevalence of childhood celiac disease and changes in infant feeding. Pediatrics 2013;131:e687-e694.
6.
White LE, Merrick VM, Bannerman E, et al: The rising incidence of celiac disease in Scotland. Pediatrics 2013;132:e924-e931.
7.
Rubio-Tapia A, Ludvigsson JF, Brantner TL, et al: The prevalence of celiac disease in the United States. Am J Gastroenterol 2012;107:1538-1544.
8.
Catassi C, Kryszak D, Bhatti B, et al: Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med 2010;42:530-538.
9.
Bai JC, Fried M, Corazza GR, et al: World gastroenterology organization global guidelines on celiac disease. J Clin Gastroenterol 2013;47:121-126.
10.
Israeli E, Hershcovici T, Grotto I, et al: Prevalence of celiac disease in an adult Jewish population in Israel. Isr Med Assoc J 2010;12:266-269.
11.
Catassi C, Rätsch IM, Gandolfi L, et al: Why is coeliac disease endemic in the people of Sahara? Lancet 1999;354:647-648.
12.
Catassi C, Doloretta Macis M, Rätsch IM, De Virgilis S, Cucca F: The distribution of DQ genes in the Saharawi population provides only a partial explanation for the high celiac disease prevalence. Tissue Antigens 2001;58:402-406.
13.
Gupta R, Reddy DN, Makharia GK, et al: Indian task force for celiac disease: current status. World J Gastroenterol 2009;15:6028-6033.
14.
Kochhar R, Dachdev S, Aggarwal A, et al: Prevalence of coeliac disease in healthy blood donors: a study from north India. Dig Liver Dis 2012;44:530-532.
15.
Makharia GK, Verma AK, Amarchand R, et al: Prevalence of celiac disease in the northern part of India: a community based study. J Clin Gastroenterol 2011;26:894-900.
16.
Yuan J, Gao J, Li X, Liu F, Wijmenga C, Chen H, Gilissen LJ: The tip of the ‘celiac iceberg' in China. Systematic review and meta-analysis. PLoS One 2013;8:e81151.
17.
Wang X, Liu W, Xu C, et al: Celiac disease in children with diarrhea in 4 cities of China. J Pediatr Gastroenterol Nutr 2011;53:368-370.
18.
Catassi C, Lionetti E: Case finding for celiac disease is ok, but is it enough? J Pediatr Gastroenterol Nutr 2013;57:415-417.
19.
Størdal K, Bakken IJ, Surén P, Stene LC: Epidemiology of coeliac disease and comorbidity in Norwegian children. J Pediatr Gastroenterol Nutr 2013;57:467-471.
20.
Catassi C, Bai JC, Bonaz B, et al: Non-celiac gluten sensitivity: the new frontier of gluten-related disorders. Nutrients 2013;5:3839-3853.
21.
Rosén A, Emmelin M, Carlsson A, Hammarroth S, Karlsson E, Ivarsson A: Mass screening for celiac disease from the perspective of newly diagnosed adolescents and their parents: a mixed-method study. BMC Public Health 2011;11:822.
22.
Lionetti E, et al: Infant feeding pattern, HLA status, and prevalence of celiac disease, in press.
23.
Alessandrini S, Giacomoni E, Muccioli F: Mass population screening for celiac disease in children: the experience in Republic of San Marino from 1993 to 2009. Ital J Pediatr 2013;39:67.
24.
Catassi C, Fasano A: Coeliac disease: the debate on coeliac disease screening - are we there yet? Nat Rev Gastroenterol Hepatol 2014;11:457-458.
25.
Lionetti E, Catassi C: Co-localization of gluten consumption and HLA-DQ2 and -DQ8 genotypes: a clue to the history of celiac disease. Dig Liver Dis 2014, Epub ahead of print.
26.
Barada K, Abu Daya H, Rostami K, Catassi C: Celiac disease in the developing world. Gastrointest Endosc Clin N Am 2012;22:773-796.
27.
Simoons FJ: Coeliac disease as a geographic problem; in Walcher DN, Kretchmer N (eds): Food, Nutrition and Evolution. New York, Masson, 1981, pp 179-199.
28.
Catassi C, Anderson RP, Hill ID, et al: World perspective on celiac disease. J Pediatr Gastroenterol Nutr 2012;55:494-499.
29.
Ammerman AJ, Cavalli-Sforza LL: The Neolithic Transition and the Genetics of Populations in Europe. Princeton, Princeton University Press, 1984, p 176.
30.
Valarini N, Maciel SM, Moura SK, Poli-Frederico RC: Association of dental caries with HLA class II allele in Brazilian adolescents. Caries Res 2012;46:530-535.
31.
Larsen CS: The agricultural revolution as environmental catastrophe: implications for health and lifestyle in the Holocene. Quat Int 2006;150:12-20.
32.
Pastore L, Carroccio A, Compilato D, et al: Oral manifestations of celiac disease. J Clin Gastroenterol 2008;42:224-232.
33.
Sánchez E, Donat E, Ribes-Koninckx C, Fernández-Murga L, Sanz Y: Duodenal-mucosal bacteria associated with celiac disease in children. Appl Environ Microbiol 2013;79:5472-5479.
34.
Tishkoff SA, Reed FA, Ranciaro A, et al: Convergent adaptation of human lactase persistence in Africa and Europe. Nat Genet 2007;39:31-40.
35.
Mehta A, Mason PJ, Vulliamy TJ: Glucose-6-phosphate dehydrogenase deficiency. Baillieres Best Pract Res Clin Haematol 2000;13:21-38.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.